Europe’s leading microbials CDMO

Capua BioServices, Europe’s largest, independent provider of high quality services in microbial contract development and manufacturing services for pharma and food industry, has announced the completion of the renovation of one of the recovery and purification plants, at its facility in Capua, Italy. In order to continuously add value to its growing customer base, Capua BioServices has designed its entire facility to be remarkably flexible; from lab - to development - to commercial production scale. This specific investment to renew this existing plant, is focused on further increasing its multi-purpose manufacturing capabilities for pharma-grade manufacturing, as Elise Mous, their Director of Sales and Marketing, explains.

The history of Capua BioServices dates back more than 50 years. It was formerly known as Patheon Capua and DSM BioSolutions and began operating as Capua BioServices in July 2015. It has a unique focus on microbial fermentation, which continues to be an important upstream bioprocess for the production of conventional and next-generation biologics. In addition, it serves as a contract manufacturer of high-value small molecules for applications in the food, feed, agrochemical and fine chemical industry. Its site in Capua contains dedicated manufacturing areas for pharmaceutical products and is regularly audited by the US FDA, EMA and specific European country authorities.

With a total fermentation capacity of about 1400 m³ spread over two separate fermentation areas, it is one of the largest independent, beta-lactam free, microbial contract manufacturing facilities in Western Europe.

To better serve its growing, global customer base, Capua BioServices continues to invest in the latest laboratory and process-scale equipment and analytical capabilities to support modern fermentation. Recently, it opened a new laboratory facility that further strengthens its ability to conduct lab and pilot-scale activities. The investment is intended to better support the onboarding of new projects and facilitate the development of processes from the start that will be practical for sustainable, large-scale manufacturing.

These latest investments in Capua BioServices’ facilities underscore their ambition to take their business to the next level, says Mrs. Mous. “Since 2015 we have exceedingly focused on serving clients in pharma and food as well as strengthening our capabilities in process development. Our key strength in our view is our ability to be very flexible: we have developed expertise in a broad diversity of process types and processing technologies that can be applied at development to commercial scale. This flexibility is also reflected in our customer base, as we serve both start-ups and large pharmaceutical companies, and anything in between.”

Mrs. Mous is confident that Capua BioServices is well positioned for continued growth, particularly given the positive outlook for microbials: microbial fermentation offers several advantages over cell culture. The processes are typically much shorter, less complex and generally more economically attractive.

Capua BioServices S.p.A.
Website: www.capuabioservices.com